RFL
Rafael Holdings Inc-Class B
NYSE · Pharmaceuticals
$1.22
+0.04 (+3.39%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.34M | 15.20M | 11.49M |
| Net Income | 4.93M | 4.84M | 3.80M |
| EPS | — | — | — |
| Profit Margin | 34.4% | 31.9% | 33.1% |
| Rev Growth | +3.8% | +5.7% | +21.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 14.34M | 15.10M | 12.46M |
| Total Equity | 42.67M | 46.21M | 51.47M |
| D/E Ratio | 0.34 | 0.33 | 0.24 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.39M | 7.34M | 5.98M |
| Free Cash Flow | 4.54M | 4.44M | 4.05M |